DRDeepak Ramanujam

Deepak Ramanujam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Deepak Ramanujam has a total of 244 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficient in vivo targeting of the myocardial scar using Moloney murine leukaemia virus complexed with nanoparticles

    by Timo Mohr, Miriam Schiffer, Deepak Ramanujam, Esther Carls, Callum M. Zgierski‐Johnston, Thomas Kok, Pia Niemann, Caroline Geisen, Peter Kohl, Stefan Engelhardt, et al.

    During myocardial infarction, native myocardium is replaced by a fibrous scar, impairing cardiac pump function and leading to potentially life‐threatening ventricular tachycardias. Gene therapy‐based targeting of the cardiac scar is essential for short‐ and long‐term treatment of post‐infarct sequelae. However, there are currently no effective methods to target and transduce cardiac (myo)fibroblasts (FB) in vivo . Therefore, Moloney murine leukaemia virus (MMLV) encoding for the fluorescent reporter mCherry complexed with magnetic nanoparticles (MNP) in combination with magnetic steering was tested. This approach strongly increased the transduction rate of FB by four‐fold in vitro . Additionally, injection of MMLV/MNP complexes into the forming scar during exposure of the heart to a magnetic field to increase virus dwell‐time 3 days after left ventricular cryo‐injury, a time when FB proliferation in the infarct peaks, yielded efficient transduction of resident FB. We further assessed the functional impact of overexpressing the gap junction protein connexin 43 (Cx43). MMLV‐mediated Cx43 overexpression (MMLV‐Cx43) in FB increased the formation of functional gap junctions in vitro and substantially lowered post‐cryo‐injury ventricular tachycardia incidence (by 50%), as demonstrated by in vivo electrophysiological testing 2 and 8 weeks after MMLV/MNP injection into the lesion. This anti‐arrhythmic effect was probably the result of a decrease in the heterogeneity of conduction around and across the scar, as observed by optical mapping in isolated hearts overexpressing Cx43. Thus, MMLV/MNP complexes combined with magnetic steering offer an efficient strategy for targeting and transducing FB in vitro and in vivo , allowing modulation of the functional properties of cardiac scars. image Key points: Genetic targeting and efficient transduction of (myo)fibroblasts (FB) in vivo are necessary to modify the properties of cardiac scars for therapeutic benefit. However, this has proven highly inadequate because of a lack of suitable viral vectors. We complexed Moloney murine leukaemia virus (MMLV) with magnetic nanoparticles (MNP) and applied a magnetic field to achieve prominent in vitro transduction of FB. Magnet‐assisted in vivo injections of MMLV/MNP complexes into the developing scar enabled efficient transduction of cardiac tissue‐resident FB. MMLV‐Cx43‐based overexpression of connexin 43 increased the density of functional gap junctions in FB in vitro . Following direct injection of the virus into the developing cardiac scar in a murine cryo‐lesion model, electrophysiological in vivo testing showed that the incidence of ventricular tachycardia was reduced by 50% at 2 and 8 weeks post‐treatment with MMLV. Our approach enables efficient targeting and transduction of FB in the cardiac scar, providing a blueprint for translation.


  • Open Access

    Contribution of VEGF-B-Induced Endocardial Endothelial Cell Lineage in Physiological Versus Pathological Cardiac Hypertrophy

    by Ibrahim Sultan, Markus Ramste, Pim Peletier, Karthik Amudhala Hemanthakumar, Deepak Ramanujam, Annakaisa Tirronen, Ylva von Wright, Salli Antila, Pipsa Saharinen, Lauri Eklund, et al.

    BACKGROUND: Preclinical studies have shown the therapeutic potential of VEGF-B (vascular endothelial growth factor B) in revascularization of the ischemic myocardium, but the associated cardiac hypertrophy and adverse side effects remain a concern. To understand the importance of endothelial proliferation and migration for the beneficial versus adverse effects of VEGF-B in the heart, we explored the cardiac effects of autocrine versus paracrine VEGF-B expression in transgenic and gene-transduced mice. METHODS: We used single-cell RNA sequencing to compare cardiac endothelial gene expression in VEGF-B transgenic mouse models. Lineage tracing was used to identify the origin of a VEGF-B-induced novel endothelial cell population and adeno-associated virus–mediated gene delivery to compare the effects of VEGF-B isoforms. Cardiac function was investigated using echocardiography, magnetic resonance imaging, and micro-computed tomography. RESULTS: Unlike in physiological cardiac hypertrophy driven by a cardiomyocyte-specific VEGF-B transgene (myosin heavy chain alpha-VEGF-B), autocrine VEGF-B expression in cardiac endothelium (aP2 [adipocyte protein 2]-VEGF-B) was associated with septal defects and failure to increase perfused subendocardial capillaries postnatally. Paracrine VEGF-B led to robust proliferation and myocardial migration of a novel cardiac endothelial cell lineage (VEGF-B-induced endothelial cells) of endocardial origin, whereas autocrine VEGF-B increased proliferation of VEGF-B-induced endothelial cells but failed to promote their migration and efficient contribution to myocardial capillaries. The surviving aP2-VEGF-B offspring showed an altered ratio of secreted VEGF-B isoforms and developed massive pathological cardiac hypertrophy with a distinct cardiac vessel pattern. In the normal heart, we found a small VEGF-B-induced endothelial cell population that was only minimally expanded during myocardial infarction but not during physiological cardiac hypertrophy associated with mouse pregnancy. CONCLUSIONS: Paracrine and autocrine secretions of VEGF-B induce expansion of a specific endocardium-derived endothelial cell population with distinct angiogenic markers. However, autocrine VEGF-B signaling fails to promote VEGF-B-induced endothelial cell migration and contribution to myocardial capillaries, predisposing to septal defects and inducing a mismatch between angiogenesis and myocardial growth, which results in pathological cardiac hypertrophy.


  • In Vivo Silencing of Regulatory Elements Using a Single AAV-CRISPRi Vector

    by P. Laurette, C. Cao, D. Ramanujam, M. Schwaderer, T. Lueneburg, S. Kuss, L. Weiss, R. Dilshat, E.E.M. Furlong, F. Rezende, et al.


  • Open Access

    Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage

    by Christina Beck, Deepak Ramanujam, Paula Vaccarello, Florenc Widenmeyer, Martin Feuerherd, Cho-Chin Cheng, Anton Bomhard, Tatiana Abikeeva, Julia Schädler, Jan-Peter Sperhake, et al.

    Recent studies of severe acute inflammatory lung disease including COVID-19 identify macrophages to drive pulmonary hyperinflammation and long-term damage such as fibrosis. Here, we report on the development of a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), as a therapeutic means against pulmonary hyperinflammation and fibrosis. MicroRNA-21 is among the strongest upregulated microRNAs in human COVID-19 and in mice with acute inflammatory lung damage, and it is the strongest expressed microRNA in pulmonary macrophages. Chemical linkage of a microRNA-21 inhibitor to trimannose achieves rapid and specific delivery to macrophages upon inhalation in mice. RCS-21 reverses pathological activation of macrophages and prevents pulmonary dysfunction and fibrosis after acute lung damage in mice. In human lung tissue infected with SARS-CoV-2 ex vivo, RCS-21 effectively prevents the exaggerated inflammatory response. Our data imply trimannose-coupling for effective and selective delivery of inhaled oligonucleotides to pulmonary macrophages and report on a first mannose-coupled candidate therapeutic for COVID-19.


  • CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver

    by Thorsten Kaltenbacher, Jessica Löprich, Roman Maresch, Julia Weber, Sebastian Müller, Rupert Oellinger, Nina Groß, Joscha Griger, Niklas de Andrade Krätzig, Petros Avramopoulos, et al.

    Genetically engineered mouse models (GEMMs) transformed the study of organismal disease phenotypes but are limited by their lengthy generation in embryonic stem cells. Here, we describe methods for rapid and scalable genome engineering in somatic cells of the liver and pancreas through delivery of CRISPR components into living mice. We introduce the spectrum of genetic tools, delineate viral and nonviral CRISPR delivery strategies and describe a series of applications, ranging from gene editing and cancer modeling to chromosome engineering or CRISPR multiplexing and its spatio-temporal control. Beyond experimental design and execution, the protocol describes quantification of genetic and functional editing outcomes, including sequencing approaches, data analysis and interpretation. Compared to traditional knockout mice, somatic GEMMs face an increased risk for mouse-to-mouse variability because of the higher experimental demands of the procedures. The robust protocols described here will help unleash the full potential of somatic genome manipulation. Depending on the delivery method and envisaged application, the protocol takes 3–5 weeks.


  • Open Access

    The long non-coding RNA NRON promotes the development of cardiac hypertrophy in the murine heart

    by Jeannine Hoepfner, Julia Leonardy, Dongchao Lu, Kevin Schmidt, Hannah J. Hunkler, Sinje Biß, Ariana Foinquinos, Ke Xiao, Kumarswamy Regalla, Deepak Ramanujam, et al.


  • Open Access

    MicroRNA-365 regulates human cardiac action potential duration

    by Dena Esfandyari, Bio Maria Ghéo Idrissou, Konstantin Hennis, Petros Avramopoulos, Anne Dueck, Ibrahim El-Battrawy, Laurenz Grüter, Melanie Annemarie Meier, Anna Christina Näger, Deepak Ramanujam, et al.

    Abnormalities of ventricular action potential cause malignant cardiac arrhythmias and sudden cardiac death. Here, we aim to identify microRNAs that regulate the human cardiac action potential and ask whether their manipulation allows for therapeutic modulation of action potential abnormalities. Quantitative analysis of the microRNA targetomes in human cardiac myocytes identifies miR-365 as a primary microRNA to regulate repolarizing ion channels. Action potential recordings in patient-specific induced pluripotent stem cell-derived cardiac myocytes show that elevation of miR-365 significantly prolongs action potential duration in myocytes derived from a Short-QT syndrome patient, whereas specific inhibition of miR-365 normalizes pathologically prolonged action potential in Long-QT syndrome myocytes. Transcriptome analyses in these cells at bulk and single-cell level corroborate the key cardiac repolarizing channels as direct targets of miR-365, together with functionally synergistic regulation of additional action potential-regulating genes by this microRNA. Whole-cell patch-clamp experiments confirm miR-365-dependent regulation of repolarizing ionic current Iks. Finally, refractory period measurements in human myocardial slices substantiate the regulatory effect of miR-365 on action potential in adult human myocardial tissue. Our results delineate miR-365 to regulate human cardiac action potential duration by targeting key factors of cardiac repolarization.


  • Open Access

    MicroRNA-21–Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload

    by Deepak Ramanujam, Anna Patricia Schön, Christina Beck, Paula Vaccarello, Giulia Felician, Anne Dueck, Dena Esfandyari, Gunter Meister, Thomas Meitinger, Christian Schulz, et al.

    Background: Cardiac macrophages (cMP) are increasingly recognized as important regulators of myocardial homeostasis and disease, yet the role of noncoding RNA in these cells is largely unknown. Small RNA sequencing of the entire miRNomes of the major cardiac cell fractions revealed microRNA-21 (miR-21) as the single highest expressed microRNA in cMPs, both in health and disease (25% and 43% of all microRNA reads respectively). MiR-21 has been previously reported as a key microRNA driving tissue fibrosis. Here, we aimed to determine the function of macrophage miR-21 on myocardial homeostasis and disease-associated remodeling. Methods: Macrophage-specific ablation of miR-21 in mice driven by Cx3cr1-Cre was used to determine the function of miR-21 in this cell type. As a disease model, mice were subjected to pressure overload for 6 and 28 days. Cardiac function was assessed in vivo by echocardiography, followed by histological analyses and single cell sequencing. Co-cultures of macrophages and cardiac fibroblasts were employed to study macrophage-to-fibroblast signaling. Results: Mice with macrophage-specific genetic deletion of miR-21 were protected from interstitial fibrosis and cardiac dysfunction when subjected to pressure overload of the left ventricle. Single cell sequencing of pressure-overloaded hearts from these mice revealed that miR-21 in macrophages is essential for their polarization towards a M1-like phenotype. Systematic quantification of intercellular communication mediated by ligand-receptor interactions across all cell types revealed that miR-21 primarily determined macrophage-fibroblast communication, promoting the transition from quiescent fibroblasts to myofibroblasts. Polarization of isolated macrophages in vitro towards a pro-inflammatory (M1) phenotype activated myofibroblast transdifferentiation of cardiac fibroblasts in a paracrine manner and was dependent on the rapid induction of miR-21 in cMPs. Conclusions: Our data indicate a critical role of cMPs in pressure overload-induced cardiac fibrosis and dysfunction and reveal macrophage miR-21 as a key molecule for the pro-fibrotic role of cMPs.


  • Open Access

    Genetic ablation of Cullin-RING E3 ubiquitin ligase 7 restrains pressure overload-induced myocardial fibrosis

    by Melanie Anger, Florian Scheufele, Deepak Ramanujam, Kathleen Meyer, Hidehiro Nakajima, Loren J. Field, Stefan Engelhardt, Antonio Sarikas

    Fibrosis is a pathognomonic feature of structural heart disease and counteracted by distinct cardioprotective mechanisms, e.g. activation of the phosphoinositide 3-kinase (PI3K) / AKT pro-survival pathway. The Cullin-RING E3 ubiquitin ligase 7 (CRL7) was identified as negative regulator of PI3K/AKT signalling in skeletal muscle, but its role in the heart remains to be elucidated. Here, we sought to determine whether CRL7 modulates to cardiac fibrosis following pressure overload and dissect its underlying mechanisms. For inactivation of CRL7, the Cullin 7 (Cul7) gene was deleted in cardiac myocytes (CM) by injection of adeno-associated virus subtype 9 (AAV9) vectors encoding codon improved Cre-recombinase (AAV9-CMV-iCre) inCul7flox/floxmice. In addition, Myosin Heavy Chain 6 (Myh6; alpha-MHC)-MerCreMer transgenic mice with tamoxifen-induced CM-specific expression of iCre were used as alternate model. After transverse aortic constriction (TAC), causing chronic pressure overload and fibrosis, AAV9-CMV-iCre inducedCul7-/- mice displayed a ~50% reduction of interstitial cardiac fibrosis when compared toCul7+/+ animals (6.7% vs. 3.4%, pCul7flox/floxMyh6-Mer-Cre-MerTg(1/0)mice which displayed a ~30% reduction of cardiac fibrosis after TAC when compared toCul7+/+Myh6-Mer-Cre-MerTg(1/0)controls after TAC surgery (12.4% vs. 8.7%, pSer473phosphorylation was increased 3-fold (pCul7-/- vs. control mice, together with a ~78% (p1152stopmutant resulted in a 16.3-fold decrease (p<0.001) of in situ end-labelling (ISEL) positive apoptotic cells. Collectively, our data demonstrate that CM-specific ablation of Cul7 restrains myocardial fibrosis and apoptosis upon pressure overload, and introduce CRL7 as a potential target for anti-fibrotic therapeutic strategies of the heart.


  • Open Access

    Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy

    by Janika Viereck, Anne Bührke, Ariana Foinquinos, Shambhabi Chatterjee, Jan A Kleeberger, Ke Xiao, Heike Janssen-Peters, Sandor Batkai, Deepak Ramanujam, Theresia Kraft, et al.

    Pathological cardiac remodelling and subsequent heart failure represents an unmet clinical need. Long non-coding RNAs (lncRNAs) are emerging as crucial molecular orchestrators of disease processes, including that of heart diseases. Here, we report on the powerful therapeutic potential of the conserved lncRNA H19 in the treatment of pathological cardiac hypertrophy. Pressure overload-induced left ventricular cardiac remodelling revealed an up-regulation of H19 in the early phase but strong sustained repression upon reaching the decompensated phase of heart failure. The translational potential of H19 is highlighted by its repression in a large animal (pig) model of left ventricular hypertrophy, in diseased human heart samples, in human stem cell-derived cardiomyocytes and in human engineered heart tissue in response to afterload enhancement. Pressure overload-induced cardiac hypertrophy in H19 knock-out mice was aggravated compared to wild-type mice. In contrast, vector-based, cardiomyocyte-directed gene therapy using murine and human H19 strongly attenuated heart failure even when cardiac hypertrophy was already established. Mechanistically, using microarray, gene set enrichment analyses and Chromatin ImmunoPrecipitation DNA-Sequencing, we identified a link between H19 and pro-hypertrophic nuclear factor of activated T cells (NFAT) signalling. H19 physically interacts with the polycomb repressive complex 2 to suppress H3K27 tri-methylation of the anti-hypertrophic Tescalcin locus which in turn leads to reduced NFAT expression and activity. H19 is highly conserved and down-regulated in failing hearts from mice, pigs and humans. H19 gene therapy prevents and reverses experimental pressure-overload-induced heart failure. H19 acts as an anti-hypertrophic lncRNA and represents a promising therapeutic target to combat pathological cardiac remodelling.